ADMA Biologics
ADMA
ADMA
360 hedge funds and large institutions have $3.28B invested in ADMA Biologics in 2025 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 98 increasing their positions, 159 reducing their positions, and 66 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
2% less funds holding
Funds holding: 368 → 360 (-8)
15% less capital invested
Capital invested by funds: $3.84B → $3.28B (-$565M)
38% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 159
Holders
360
Holding in Top 10
6
Calls
$69.2M
Puts
$32.9M
Top Buyers
| 1 | +$131M | |
| 2 | +$74.9M | |
| 3 | +$47.7M | |
| 4 |
CP
Caligan Partners
New York
|
+$38.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$31.1M |
Top Sellers
| 1 | -$45.1M | |
| 2 | -$36.4M | |
| 3 | -$32.8M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$32.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$30.4M |
